• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172411 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
# p; E0 P6 R: u; G4 s' z7 Z
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  9 S0 }. x8 N4 z' ~

8 p: t, B/ `* |2 p3 h: O) A& f
9 V0 q. W; F: R  K- J$ k" \Sub-category:
7 t8 Z- i) [# X, d/ Q+ T, K( K- q8 [Molecular Targets
& u6 ^0 W* d2 ?" G
, J" l8 h% ]* D0 I  c! u3 f2 f
6 o+ e% t! b& U0 v; _% KCategory:
4 F5 r4 \1 r' Z- n+ STumor Biology
# q- W. z9 }9 I1 Y6 Z8 s) ]1 H. R2 ]/ ~) H! e' X+ u

* L1 B9 x( v( }, F& vMeeting:7 e( e6 z- ]& O
2011 ASCO Annual Meeting
7 o. O9 ~2 z, [9 `% u& R
& ?# J  E( b- f  V; _9 B, K+ X
: C8 j( E9 d' t$ B0 a' k$ \Session Type and Session Title:
. y! k3 T1 ]! K+ I  t* rPoster Discussion Session, Tumor Biology - j# J1 C; ~" [& p
* E9 }+ y5 P8 _- U+ o/ _

6 g$ ?& l" b' Z8 K8 TAbstract No:: s) u( U. J, q( R5 E# @5 Q
10517 % m7 x! E4 j+ A! K

: i8 L+ V; E$ N- I9 q8 i) h& M: J2 K' b6 }* d1 o" M/ F
Citation:& O( K) J& n5 V% K9 r% N9 O
J Clin Oncol 29: 2011 (suppl; abstr 10517)
. v# B- i# F/ O1 I' \/ H+ A
& h. z6 W6 g* y/ I9 T6 N9 K# j1 R' O$ h9 n: [7 Z, j/ x
Author(s):
+ ~6 S: s, g/ f7 N3 u* H* y& F1 NJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
$ c& k, W5 G  Y" p! K( G; k/ d/ |' a+ g

% z$ P0 h1 i( U/ i" }# x
: q& K1 t" A3 x/ \5 b8 e9 sAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.6 S& @% c! F0 [: f

6 ]2 k- A4 r0 y$ e7 Q4 @Abstract Disclosures
6 z% p$ D! o% d, F3 B# E  v
: g; y& k  }7 O$ f  l/ EAbstract:
) S4 r# v. U" d' n+ v
+ N" b2 t0 ^- {. o* i8 l1 ^( s  o7 x  D' @' U
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; s+ m" f, b) A" @6 N

5 k* `. j' a* w: s ( `: O: z9 s# T2 k! [
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ; b6 [6 J& t- O8 u. F1 `1 r
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

/ K! e. f4 l" z8 f# O9 q化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
! g+ b+ a# d& N1 I2 P4 M" y+ y易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。" e5 Q" Y# V- ?, o7 j- r
ALK一个指标医院要900多 ...

" D4 N8 G# x3 t6 }平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
3 `1 U7 X1 s) R, ?7 H! J2 _% A4 u3 n6 W0 i; G8 f; V( R
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表